Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novavax

FDA advisers recommend Novavax COVID shot in adults

Officials said Novavax could fill an unmet need because there aren't non-mRNA COVID vaccines that can serve as first line defenses.

Axios

FDA advisers back Novavax COVID-19 shots as new US option

A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market

The Independent UK

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novavax Stock Jumps After FDA Advisors Endorse Its Covid Shot

An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. After yo-yoing Wednesday, NVAX stock settled up.

Investors Business Daily

Novavax's new shot may sway anti-vaxxers

Experts hope the new COVID vaccine, which uses older biotechnology, could help the unvaccinated come around

Salon

US FDA Concerned over Potential Novavax Myocarditis Risk

The Food and Drug Administration voiced concern Friday about myocarditis being potentially linked to the Novavax Covid-19 vaccine, just as experts are to weigh its use in the United States. The Novavax vaccine is already authorized in other countries, particularly in Europe. In the United States, an independent committee convened…

Asharq Al-Awsat

Novavax COVID shot effective but carries heart risk, FDA says

Novavax evaluation comes days before key FDA meeting

Axios

Read news from The Economist, FT, and more,
with one subscription

Novavax Crashes After FDA Suggests Its Covid Vaccine Causes Heart Inflammation

Investors Business Daily

Novavax hopes its COVID shot wins over FDA, vaccine holdouts

Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine

The Independent UK

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Tribune News Service

$100 Invested In Novavax 5 Years Ago Would Be Worth This Much

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 9.78% on an annualized basis producing an average annual return of 19.75%. Currently, Novavax has a market capitalization of $3.69 billion.

Benzinga

Why Novavax Shares Are Diving Today

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 14.20% at $50.14. Bank of America's Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Benzinga

What Are Whales Doing With Novavax

Someone with a lot of money to spend has taken a bullish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Novavax Has Limited Pipeline Upside, Says BofA Analyst: What's Next?

Although Novavax, Inc’s (NASDAQ: NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities. The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Upgrades

Los Angeles Times

With old-school technology, can Novavax win over COVID vaccine skeptics?

Since their debut just 18 months ago, three COVID-19 vaccines have saved an estimated 2.2 million American lives, changed the trajectory of a pandemic and inspired all manner of conspiracy theories.

Benzinga

Moderna Concludes FDA Submission For Its COVID-19 Shot In Adolescents, Kids

Reuters reported that Moderna Inc (NASDAQ:MRNA) had made required submissions to the FDA for emergency use authorization of its COVID-19 vaccine in adolescents and children. An advisory panel of experts to the U.S. drug regulator will meet in June to review the request. Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For…

Benzinga

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Novavax Stock Is Plunging Today

Novavax Inc (NASDAQ: NVAX) shares are trading lower Tuesday after the company reported worse-than-expected financial results.

Benzinga

Novavax's 22% Post-Earnings Plunge: 5 Factors That Took Toll

Novavax, Inc. (NASDAQ: NVAX) shares slumped 22.27% after-hours on Monday, reacting to its quarterly financial report.

Benzinga

Check Out What Whales Are Doing With NVAX

Investors Business Daily

Novavax Crashes As Alternative To Pfizer, Moderna Covid Shots Lags Estimates

Novavax reported lighter-than-expected first-quarter sales and profit after launching its Covid vaccine in November. NVAX stock fell.

Benzinga

Why Novavax Shares Are Falling After Hours

Novavax Inc (NASDAQ: NVAX) shares are trading lower in Monday's after-hours session after the company reported worse-than-expected financial results.

Benzinga

How Novavax Stock Looks Headed Into Q1 Earnings

Novavax, Inc. (NASDAQ: NVAX) is set to print its first-quarter financial results after the market close on Thursday. The stock was trading more than 6% lower, at one point, heading into the event.

Benzinga

Earnings Preview: Novavax

Novavax (NASDAQ:NVAX) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Novavax will report an earnings per share (EPS) of $2.69.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.